Connect with us


“In an industry as broad as femtech, there is untapped potential and fiscal gain to be had – for founders and investors alike”

By Grace Tucker, strategist and media relations specialist



Grace Tucker

While health tech as an industry has continued to boom in the UK, there remains a wide disparity when it comes to femtech and female founders.

It’s no secret that the UK, and particularly London, is a hub of innovation and investment. 

Second only to California’s Silicon Valley, 2022 saw London’s start-up ecosystem valued at US$314bn, with the UK capital taking the top spot globally for fintech, according to the 2022 Global Startup Ecosystem Report.

In the wake of Covid, health tech in particular has experienced a significant upward trajectory, providing digital-first access to patients in lieu of face to face care, or a lack thereof entirely as we continue to witness NHS waiting lists increase in the UK.

But while health tech as an industry has continued to boom in the UK, which is now home to a vast range of unicorns, there remains a wide disparity when it comes to femtech and female founders, which make up only six per cent of UK unicorns.

According to the Q3 2022 Femtech in the UK report by Femtech Analytics, the total funding of the femtech sector in the UK has exceeded £648m.

While indeed a vast and growing sum, this accounts for just over 0.2 per cent of the value of London’s start-up ecosystem, despite the fact that women are 75 per cent more likely to access digital healthcare than men.

If we consider not only the vast investment being funnelled into UK tech, but equally that the UK boasts the widest gender health gap of any G20 nation, femtech investment really poses a no-brainer for VCs looking to diversify their portfolio. 

Not in the least because International Women’s Day is fast approaching, but because women represent 50 per cent of the world’s population and are underrepresented in health research. 

Below are some of the many femtech companies in the UK disrupting and ultimately innovating healthcare for health equality everywhere.


While still without a known cure or cause, endometriosis affects one in ten women in the UK and is the country’s second most common gynaecological condition, according to Endometriosis UK.

Most women are unaware of having this condition, with average diagnosis wait times sitting between a staggering seven and eight years. It’s clear that there more needs to be done here, and Syrona Health is one UK femtech leading the charge.

Founded by Chantelle Bell and Anya Roy, Syrona Health is building the future of gynaecological health condition management.

Their expert team of scientists and doctors is working to close the gender health gap and establish health equality by creating accessible care for all gynaecological conditions, and contributing to wider medical research.

Having recently completed their seed funding round which attracted US$2m, Syrona Health is certainly one to watch in the femtech space.


This section needs no introduction: sex is a vital part of human life. Establishing a healthy understanding of sexual desire, need and practice is well-documented to improve both mental and physical health, and yet remains a taboo conversation topic for many.

Whether a result of cultural, educational or other factors, we still don’t talk enough about sex.

This aversion is reflected in sextech funding, making up only 0.29 per cent of femtech funding worldwide in 2022.

Fortunately, we are beginning to witness a shift, with founders tackling this taboo to promote and educate healthy attitudes towards sex and sexual wellbeing. 

One such organisation is Ferly, whose app offers expert insight, courses, workshops and guided practices to help users to break stigma, dispel shame and ultimately empower themselves to lead healthy, confident and pleasurable lives.

Another UK femtech company which focuses on sexual wellbeing is Blueheart, which provides digital sex therapy via their AI-powered app, to help users improve intimate connection with partners and themselves with insights from world-renowned sex practitioners. 

Mental health

Mental health problems are on the rise in the UK, according to mental health charity Mind. 

Despite the fact that mental health issues are prevalent in all genders and that specific causes are complicated and can be difficult to root out, research has found that women are more likely to suffer suicidal thoughts than men. Equally, women are twice as likely to suffer from anxiety than men, and more likely to suffer from depression.

Enter femtech startups like Clementine, hailed as ‘one of the seven apps every woman should own’ by The Guardian. If you haven’t already heard of Clementine, consider this your reminder to check it out.

Incorporating hypnotherapy practices, Clementine supports women to build confidence, reduce anxiety and stress and help women boss it, to put it plainly. With pick-me-up sessions, sleep hygiene courses, confidence boosters and more, Clementine is the app helping women become their best selves.

Having secured US$1m in seed funding in 2020 from Fortunis Capital, it would appear that the mental health femtech space is poised to continue on its journey of growth for women everywhere.

Reproductive health & fertility

Leading the charge of femtech, reproductive health and fertility make up 2.98 per cent and 2.67 per cent of all femtech funding respectively, inclusive of pregnancy and nursing.

In the UK, statistically one in seven may have difficulty conceiving, between nine and 15 per cent of couples. For femtech companies and investors, this offers the opportunity to expand within a lucrative sector that is in a flow state of scaling up and constantly evolving.

A good example is Béa Fertility, the world’s first at-home, clinical grade fertility treatment, at affordable prices.

From ovulation tracking, at-home insemination and pregnancy testing, Béa Fertility is supported and led by clinical experts to support all customers through their fertility journey.

It is a monthly subscription service built on a direct-to-consumer model, which specifically also caters to the LGBTQ+ community, to democratise the fertility process with inclusive, affordable care. 

Looking forward, and beyond the organisations listed above, there’s ample space for early movers to stake out new opportunities in an innovative space.

In 2022, female founders attracted under 12 per cent of investments into UK firms, even though just under 17 per cent of all active companies are led by women.

In an industry as broad as femtech, there is untapped potential and fiscal gain to be had, for founders and investors alike.

In order to increase representation, grow a balanced, diverse economy, and close the gender health gap, femtech is a vital step forward.

As digital health solutions continue to take over the market, now is the time to look to groundbreaking startups and scaleups making significant impact to the health and lives of women globally – investors, on your marks. 


Grace Tucker is a consultant, strategist, and media relations specialist. She is senior account manager at The Media Foundry, a PR and comms agency for start-ups and growing businesses across all areas of tech, media and the third sector.


The continued struggle for female representation in drug trials  

Dr Janet Choi, chief medical officer at Progyny



Dr Janet Choi, chief medical officer at Progyny

The exclusion of women from drug trials undermines efforts to ensure equitable and effective healthcare for all individuals.

In 2002, the Women’s Health Initiative (WHI) was forced to pause its study on hormone therapy’s effect on menopause symptoms due to results showing it increased the risk for breast cancer, stroke and heart disease, and thrombotic events like pulmonary emboli.

Over 20 years later, in May of this year, JAMA published a review of this study and determined that, given current available hormone therapy formulations as well as risk/benefit analysis, younger menopausal women may actually derive significant benefits from menopausal symptom relief with appropriately prescribed hormone therapies.

The initial study had looked at women who were older and typically years post-menopause – the average age of the study participants was 63.3 years – and the age-related changing of blood vessels, among other things, may be the key to shifting from greater risk to greater benefit with hormone therapy.

I wish this more measured summary of the study’s findings and recommendations had been headlined back in 2002 – and I imagine thousands of my OB/GYN colleagues and billions of menopausal women over the years feel the same.

Yet, due to these 2002 over-generalised published findings, doctors and patients shied away from hormone therapy, which led to unnecessary suffering for many symptomatic menopausal women.

The irony of the WHI study is that after decades of women being excluded from clinical research, Congress finally passed an act in 1993 requiring that the National Institute of Health (NIH) enrol women and persons of colour in clinical trials.

On the heels of this landmark decision, the intentions of the WHI study were excellent – a first of its kind for women – but may have unintentionally set back women’s health innovation.

The reality

If you’re wondering why we are just now reevaluating and reinterpreting findings made in a 2002 women’s health study you may (or may not) be shocked to learn that while there is growing inclusion of women into research trials, they are still underrepresented in key therapeutic research areas, such as cancer and cardiovascular disease.

Excluding women from drug trials can have several harmful consequences. First, it can lead to a lack of understanding about how medications affect women differently than men, as their physiological responses may vary due to hormonal and metabolic differences, among other factors.

This can result in ineffective or potentially harmful treatments for women. It can also hinder progress in medical research by preventing the development of sex-specific treatment approaches.

Additionally, while the amount of research conducted on the behalf of women has grown in the past two decades, research involving pregnant women has been restricted.

This leads to a limited understanding of how best to medically care for pregnant women: for example, less than 10 per cent  of prescription medications have been studied enough to understand the impact in pregnancy on both the woman and her foetus.

While the NIH and American College of Obstetricians and Gynecologists (ACOG) both acknowledge pregnancy as a “medically complex” state that can alter metabolism of medications, and the course of various diseases, increased pregnancy-specific data needs to be collected to optimise the care of women in pregnancy.

Another recent, glaring case study: initial COVID vaccination trials did not include pregnant women, which led to restrictions on the availability of the vaccines as well as restrictions of the use in pregnant women with dire consequences – as unvaccinated pregnant women are more likely to develop severe COVID infections requiring ICU admissions and are more likely to develop other pregnancy-related complications like preeclampsia and preterm birth.

How do we move forward?

The exclusion of women from drug trials undermines efforts to ensure equitable and effective healthcare for all individuals.

It’s crucial for the government and pharmaceutical companies to put more resources and funding into women’s health so we can have a deeper understanding of how to treat diseases that impact over half of the population, for more female and diverse talent to enter the medical field – either as doctors, researchers, healthcare executives – and to incorporate how biological sex can affect medical treatment into provider education.

And, for pregnant women, the answer was proposed by ACOG back in 2015: “A more careful examination…points to the need for evidence-based consideration of pregnancy exposure in research rather than broad exclusion of all pregnant women”.

If evidence demonstrates minimal risk to the foetus as well as potential benefit to the pregnant woman, why should she be denied the right to give informed consent to enrol in a clinical trial?

To receive the Femtech World newsletter, sign up here.

Continue Reading


‘Women are left in limbo’: how telemedicine can cut down NHS gynaecology waiting times

By Kat James, director of new projects at Consultant Connect



Almost 600,000 people in England are waiting for gynaecology treatment. It is clear the current system is not fit for purpose.

The NHS, across the board, is struggling to reduce waiting lists, but gynaecology health, in particular, has been sent to the back of the queue.

Referral numbers are about 60 per cent higher than pre-pandemic, which represents one of the three highest specialties in terms of volume increase since pre-COVID.

Not only are women left feeling neglected, but longer wait times also result in them needing more complex treatment or even emergency admissions to hospital.

Then, there is also the impact on family life, work, and women’s mental health. A survey of the Royal College of Obstetricians and Gynaecologists found that four-fifths (80 per cent) of women said their mental health has worsened due to the wait and that one in four of those whose mental health had deteriorated, pain was given as a reason.

More than three-quarters (77 per cent) of women said their ability to work or participate in social activities had been negatively impacted.

One of the main stumbling blocks impacting patient waiting times is the disconnect between primary and secondary care. Often, patients who have faced long waits for their appointment are discharged after their first hospital appointment and told that their care is best taken care of by their GPs.

The good news is that new ways of working better connect primary and secondary care and ensure patients receive the right treatment first time. If applied at scale, these solutions considerably reduce waiting lists.

For example, giving GPs immediate access to speak to a consultant on the phone for specialist advice and guidance for their patient. In ordinary circumstances, a GP would have to call the hospital switchboard or send a written advice request which might take days to be answered.

Often, these queries would go unanswered or aren’t transferred to the correct department, resulting in patients being referred sometimes unnecessarily or presenting at a busy A&E department.

Technology like Consultant Connect allows GPs to directly “hunt down” a specialist consultant from a pre-defined rota for expert advice via a phone call, ensuring GPs can direct their patients to the right care first time. This service is available for gynaecology in almost 50 NHS areas across the country.

In Coventry, for example, a 54-year-old patient presented with obvious advanced gynaecological cancer. While the two-week wait referral had already been made, the GP couldn’t move the appointment sooner than 14 days later.

Meanwhile, the patient started deteriorating, and the GP considered an urgent admission. The GP used Consultant Connect and, within seconds, was connected to a gynaecologist, who then arranged for the patient to be scanned that day. The patient got the care they needed and avoided an acute admission.

In June 2023, the service expanded to cover a menopause advice and guidance line as referral data in one local area showed increased referrals relating to menopause-specific questions, many of which did not require to be seen in a hospital setting.

This meant that trusts weren’t seeing patients who needed to be seen, and patients with menopause symptoms were on waiting lists for a prolonged duration without management plans.

With the new Consultant Connect Menopause line, GPs can get through to a consultant with special interest in menopause matters within 26 seconds.

Data shows that 87 per cent of calls resulted in the GP receiving “enough” advice for their patient to benefit from an immediate treatment plan via their GP rather than waiting for a hospital appointment with a specialist unnecessarily.

Another way to tackle the wait problem is to leverage remote ways of working, which opens access to a new pool of workforce that otherwise wouldn’t exist.

Consultant Connect runs a network of NHS consultants who review gynaecology referrals remotely, with no need to travel to local hospitals and with consultants choosing their own working hours. This is often attractive to consultants who work part-time in hospital or are on parental leave, for example.

For patients, it means they get access to treatment plans faster: the remote working consultant determines the urgency of a referral and writes up a management plan, which means that treatment can start immediately.

Often, the health problem can be resolved through this plan, and for those still needing to be seen, it means they come to their first appointment on a more informed basis.

At the same time, it ensures patients are on the correct pathway, and any diagnostic test needed for a diagnosis are initiated in a timely manner.

Last year, Consultant Connect’s team triaged over 5,000 gynaecology referrals across the UK, resulting in 43 per cent of referrals being safely removed from the waiting list.

Many of these patients were returned to their GP with a treatment plan devised by the consultant. By fast-tracking urgent cases, women are not put through unnecessary stress and pain while waiting to be referred to a gynaecologist. Among these referrals, one in ten cases were upgraded to the urgent and suspected cancer pathways.

By reviewing current systems to make them more joined up and to allow for efficient ways of working, we can speed up care for women and make sure that clinicians have the right tools to help the NHS deal with the mounting gynaecology backlog.

To receive the Femtech World newsletter, sign up here.

Continue Reading


‘We are not allowed to talk about our bodies’: why we need to address social media censorship

By Clio Wood, women’s health advocate and founder of &Breathe



Social media censorship is just another example of women’s issues being sidelined and women being made, yet again, to feel small.

The gender data gap is huge and, if you’ve ever read the great Caroline Criado Perez’s book, Invisible Women, you’ll know what I mean. It touches every day of a female life.

That impact includes social media too. Because while the social media platforms are notoriously secretive about their internal workings, it’s a pretty safe bet that social media algorithms, like most of the rest of life, are built on male data and trained on male behaviours.

This means that as long as women have different behaviours and priorities of what they want to see on these platforms, we’re going to find it a struggle.

Meta and Tiktok are silencing women’s health and sexual wellbeing content. Censorship harms women’s health: it increases women’s pain, and disempowers women, which in turn means the gender health gap cannot close. What annoys you when you’re on your phone scrolling has long-lasting impact for us and our children.

I’ve experienced this censorship first hand on Instagram, with my reach being restricted for simply posting a body confidence reel of me dancing in a bikini.

That in itself – one example of many – is infuriating, but what’s especially galling is that everyday men’s health topics are left uncensored, and hyper sexualised women’s bodies, unsolicited “dick pics” and fake accounts using nearly naked female profile pictures are making their way into social media feeds and inboxes unchecked. The hypocrisy of the situation is clear.

All the while charities are being forced to use male nipples instead of female ones, and female-led period brands are losing hundreds of thousands of pounds when their ad accounts get deleted.

Creators, charities, medical practitioners and brands are being censored constantly through algorithms picking up words like sex, vagina, vulva, or period. Which are all normal human functions or body parts and integral to these creators’ missions. You can’t be a period care brand without talking about periods.

CensHERship aims to alter the trajectory of the current algorithms and end the routine censorship of women’s health content online

Creators end up using written symbols and numbers to disguise these words and bleep them out in speech to try to get around this censorship.

It’s examples like this that finally led me – after many years of finding this situation ridiculous – to do something about it.

Together with Anna O’Sullivan, we’ve created CensHERship, a campaign which aims to alter the trajectory of the current algorithms and hopefully restore some balance to what is allowed on social media. Our ultimate aim is to bring the platforms to the table for discussion by this time next year.

We launched a survey in late January 2024 to try to collect as much information as we can about the incidences of muting and censorship that female creators are experiencing, whether they are educators, charities, brands or medical professionals. The results emphasised that this is a widespread issue taking in all of women’s health and sexual wellbeing.

In tandem we hosted an intimate roundtable to launch the CensHERship campaign and found, to our astonishment, that the problem goes much deeper than social media. Women’s health and sexual wellbeing brands are being refused bank accounts, insurance and being kicked off payment platforms without warning.

Social media censorship is just the tip of the iceberg. It’s just one more example of women’s issues being sidelined and women being made, yet again, to feel small.

We’re not being allowed the freedom to talk about our own bodies and health, because speaking up goes against the male-gaze archetype of the female role and body. Let’s end CensHERship once and for all.

Clio Wood is a women’s health advocate, journalist, author and Founder of &Breathe.

Anna O’Sullivan is a communications and marketing professional and writes FutureFemHealth 

Continue Reading


Copyright © 2023 Aspect Publishing Ltd. All Rights Reserved.